Bassler Bonnie L — SEC insider filings

SEC reporting owner CIK 1683607. 67 insider filings on record with FilingPulse; latest filed 2026-09-30.

Transaction summary — filings shown

Covers the 50 most recent of 67 filings on record, filed 2022-04-01 to 2026-09-30. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.

By issuer — same filings

Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.

IssuerRole (as filed)FilingsPurchases (P)Sales (S)Other legs
REGENERON PHARMACEUTICALS, INC. (REGN)Director20—19 legs · 17,064 sh · $14,541,74546
Royalty Pharma plc (RPRX)Director24——24
Cidara Therapeutics, Inc. (CDTX)Director6——13

Insider filings — Bassler Bonnie L

FiledFormIssuerReported transactionsSource
2026-09-304Royalty Pharma plc (RPRX)Grant/award (A): 642 @ $58.41EDGAR
2026-06-304Royalty Pharma plc (RPRX)Grant/award (A): 689 @ $54.40EDGAR
2026-06-084Royalty Pharma plc (RPRX)Grant/award (A): 4,545 @ $0EDGAR
2026-03-314Royalty Pharma plc (RPRX)Grant/award (A): 815 @ $45.98EDGAR
2026-01-084REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 1,500 @ $374.12 · Sale (S): 1,500 @ $800 · Option exercise (M): 1,500 (derivative) @ $0EDGAR
2026-01-074Cidara Therapeutics, Inc. (CDTX)Disposition to issuer (D): 15 @ $221.50 · Disposition to issuer (D): 1,750 (derivative) · Disposition to issuer (D): 875 (derivative) · Disposition to issuer (D): 1,400 (derivative) · Disposition to issuer (D): 2,125 (derivative) · Disposition to issuer (D): 2,125 (derivative) · +2 moreEDGAR
2026-01-064REGENERON PHARMACEUTICALS, INC. (REGN)Grant/award (A): 155 @ $0 · Grant/award (A): 1,962 (derivative) @ $0EDGAR
2026-01-024Royalty Pharma plc (RPRX)Grant/award (A): 967 @ $38.74EDGAR
2025-11-244REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 760 @ $371.40 · Sale (S): 760 @ $750 · Option exercise (M): 760 (derivative) @ $0EDGAR
2025-09-304Royalty Pharma plc (RPRX)Grant/award (A): 1,047 @ $35.79EDGAR
2025-06-304Royalty Pharma plc (RPRX)Grant/award (A): 1,064 @ $35.24EDGAR
2025-06-184Cidara Therapeutics, Inc. (CDTX)Grant/award (A): 11,100 (derivative) @ $0EDGAR
2025-05-144Royalty Pharma plc (RPRX)Grant/award (A): 7,614 @ $0EDGAR
2025-04-014Royalty Pharma plc (RPRX)Grant/award (A): 1,141 @ $32.87EDGAR
2025-01-064REGENERON PHARMACEUTICALS, INC. (REGN)Grant/award (A): 166 @ $0 · Grant/award (A): 1,958 (derivative) @ $0EDGAR
2025-01-024Royalty Pharma plc (RPRX)Grant/award (A): 1,503 @ $24.94EDGAR
2024-12-194Cidara Therapeutics, Inc. (CDTX)Grant/award (A): 16,000 (derivative) @ $0EDGAR
2024-09-304Royalty Pharma plc (RPRX)Grant/award (A): 1,342 @ $27.92EDGAR
2024-08-194REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 756 @ $371.40 · Sale (S): 756 @ $1,170 · Option exercise (M): 756 (derivative) @ $0EDGAR
2024-08-054REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 756 @ $371.40 · Sale (S): 756 @ $1,115 · Option exercise (M): 756 (derivative) @ $0EDGAR
2024-07-194Cidara Therapeutics, Inc. (CDTX)Grant/award (A): 2,125 (derivative) @ $0EDGAR
2024-06-284Royalty Pharma plc (RPRX)Grant/award (A): 1,399 @ $26.80EDGAR
2024-06-254REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 756 @ $371.40 · Sale (S): 756 @ $1,062 · Option exercise (M): 756 (derivative) @ $0EDGAR
2024-06-104Royalty Pharma plc (RPRX)Grant/award (A): 9,293 @ $0EDGAR
2024-06-074REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 827 @ $380.95 · Sale (S): 827 @ $1,011 · Option exercise (M): 827 (derivative) @ $0EDGAR
2024-04-024Royalty Pharma plc (RPRX)Grant/award (A): 1,240 @ $30.23EDGAR
2024-02-264REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 854 @ $391.92 · Sale (S): 854 @ $979.25 · Option exercise (M): 854 (derivative) @ $0EDGAR
2024-01-314REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 827 @ $380.95 · Sale (S): 827 @ $959 · Option exercise (M): 827 (derivative) @ $0EDGAR
2024-01-044REGENERON PHARMACEUTICALS, INC. (REGN)Grant/award (A): 135 @ $0 · Option exercise (M): 826 @ $380.95 · Sale (S): 826 @ $914 · Option exercise (M): 826 (derivative) @ $0 · Grant/award (A): 1,607 (derivative) @ $0EDGAR
2023-12-294Royalty Pharma plc (RPRX)Grant/award (A): 1,353 @ $27.71EDGAR
2023-12-144REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 610 @ $376.69 · Sale (S): 610 @ $870 · Option exercise (M): 610 (derivative) @ $0EDGAR
2023-10-034Royalty Pharma plc (RPRX)Grant/award (A): 1,384 @ $27.08EDGAR
2023-08-234REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 853 @ $391.92 · Sale (S): 853 @ $829 · Option exercise (M): 853 (derivative) @ $0EDGAR
2023-08-114REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 853 @ $391.92 · Sale (S): 853 @ $789 · Option exercise (M): 853 (derivative) @ $0EDGAR
2023-06-304Royalty Pharma plc (RPRX)Grant/award (A): 1,208 @ $31.03EDGAR
2023-06-264Royalty Pharma plc (RPRX)Grant/award (A): 7,747 @ $0EDGAR
2023-06-234Cidara Therapeutics, Inc. (CDTX)Grant/award (A): 42,500 (derivative) @ $0EDGAR
2023-03-314Royalty Pharma plc (RPRX)Grant/award (A): 1,049 @ $35.73EDGAR
2023-03-274REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 1,240 @ $380.95 · Sale (S): 1,240 @ $818 · Option exercise (M): 1,240 (derivative) @ $0EDGAR
2023-02-074REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 1,021 @ $380.95 · Sale (S): 1,021 @ $779 · Option exercise (M): 1,021 (derivative) @ $0EDGAR
2023-01-054REGENERON PHARMACEUTICALS, INC. (REGN)Grant/award (A): 165 @ $0 · Grant/award (A): 1,929 (derivative) @ $0EDGAR
2023-01-034Royalty Pharma plc (RPRX)Grant/award (A): 943 @ $39.76EDGAR
2022-12-124REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 218 @ $380.95 · Sale (S): 218 @ $779 · Option exercise (M): 218 (derivative) @ $0EDGAR
2022-09-304Royalty Pharma plc (RPRX)Grant/award (A): 913 @ $41.06EDGAR
2022-09-124REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 1,279 @ $391.92 · Sale (S): 1,279 @ $705 · Option exercise (M): 1,279 @ $391.92 · Sale (S): 1,279 @ $686.99 · Option exercise (M): 609 @ $376.69 · Sale (S): 609 @ $741 · +3 moreEDGAR
2022-06-304Royalty Pharma plc (RPRX)Grant/award (A): 903 @ $41.52EDGAR
2022-06-244Cidara Therapeutics, Inc. (CDTX)Grant/award (A): 28,000 (derivative) @ $0EDGAR
2022-06-244Royalty Pharma plc (RPRX)Grant/award (A): 6,328 @ $0EDGAR
2022-04-114REGENERON PHARMACEUTICALS, INC. (REGN)Option exercise (M): 1,240 @ $380.95 · Sale (S): 1,240 @ $725 · Option exercise (M): 1,240 (derivative) @ $0EDGAR
2022-04-014Royalty Pharma plc (RPRX)Grant/award (A): 964 @ $38.87EDGAR

FilingPulse's Form 4 archive currently extends back to 2020-09-21 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.

Need this as JSON? GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1683607 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs